3D Bioprinting Market

Executive Summary

3D Bioprinting Market was valued at US $2.15 billion in 2021 and is projected to grow at 19.31% CAGR over the forecast period to reach US $6.19 billion by 2027. 3D Bioprinting Market represented US $0.64 billion opportunity over 2019-2021 and estimated to create US $4.05 billion opportunity in 2027 over 2021.

3D Bioprinting from Consainsights analyses the 3D Bioprinting Market in the Life Sciences industry over the forecast period to 2027.

3D Bioprinting research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

3D Bioprinting segmentation includes Component, Material, Application, End User, Region and Geography.

Based on the Component, the 3D Bioprinting analysis covers Bioprinters, Bioinks.

In Component segment, Bioprinters segment has highest cagr growth of 16.99%.

Based on the Material, the 3D Bioprinting analysis covers Living Cells, Hydrogels, Extracellular Matrices, Other Biomaterials.

In Material segment, Living Cells segment has highest cagr growth of 16.99%.

Based on the Application, the 3D Bioprinting analysis covers Research Applications, Clinical Applications.

In Application segment, Research Applications segment has highest cagr growth of 16.99%.

Based on the End User, the 3D Bioprinting analysis covers Research Organizations & Academic Institutes, Biopharmaceutical Companies, Hospitals.

In End User segment, Research Organizations & Academic Institutes segment has highest cagr growth of 16.99%.

Based on the Region, the 3D Bioprinting analysis covers North America, Europe, Asia Pacific, Rest of the World.

In Region segment, North America segment has highest cagr growth of 16.99%.

Based on the region, the 3D Bioprinting analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Advanced Solutions Life Sciences, Allevi Inc., Aspect Biosystems Ltd., Cellink, Cyfuse Biomedical K.K., Digilab, Inc., Envisiontec, Gesim, Nano3D Biosciences, Inc., Organovo Holdings, Inc., Poietis, Regenhu, Regenovo Biotechnology Co., Ltd., Rokit Healthcare, Tevido Biodevices and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Component

Introduction

In 2021, Bioprinters segment has the highest revenue of US $0.94 billion and is expected to grow at CAGR of 16.99% by 2027 Bioprinters segment has highest cagr growth of 16.99%.

Bioprinters

Bioprinters segment was valued at US $0.66 billion in 2019 and is projected to grow at 16.99% CAGR over the forecast period to reach US $2.70 billion by 2027. Bioprinters segment represented US $0.28 billion opportunity over 2019-2021 and estimated to create US $1.76 billion opportunity in 2027 over 2021.

Bioinks

Bioinks segment was valued at US $0.41 billion in 2019 and is projected to grow at 16.99% CAGR over the forecast period to reach US $1.66 billion by 2027. Bioinks segment represented US $0.17 billion opportunity over 2019-2021 and estimated to create US $1.09 billion opportunity in 2027 over 2021.

Material

Introduction

In 2021, Living Cells segment has the highest revenue of US $0.87 billion and is expected to grow at CAGR of 16.99% by 2027 Living Cells segment has highest cagr growth of 16.99%.

Living Cells

Living Cells segment was valued at US $0.61 billion in 2019 and is projected to grow at 16.99% CAGR over the forecast period to reach US $2.52 billion by 2027. Living Cells segment represented US $0.26 billion opportunity over 2019-2021 and estimated to create US $1.65 billion opportunity in 2027 over 2021.

Hydrogels

Hydrogels segment was valued at US $0.41 billion in 2019 and is projected to grow at 16.99% CAGR over the forecast period to reach US $1.67 billion by 2027. Hydrogels segment represented US $0.17 billion opportunity over 2019-2021 and estimated to create US $1.09 billion opportunity in 2027 over 2021.

Extracellular Matrices

Extracellular Matrices segment was valued at US $0.29 billion in 2019 and is projected to grow at 16.99% CAGR over the forecast period to reach US $1.18 billion by 2027. Extracellular Matrices segment represented US $0.12 billion opportunity over 2019-2021 and estimated to create US $0.77 billion opportunity in 2027 over 2021.

Other Biomaterials

Other Biomaterials segment was valued at US $0.20 billion in 2019 and is projected to grow at 16.99% CAGR over the forecast period to reach US $0.82 billion by 2027. Other Biomaterials segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.53 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Research Applications segment has the highest revenue of US $1.09 billion and is expected to grow at CAGR of 16.99% by 2027 Research Applications segment has highest cagr growth of 16.99%.

Research Applications

Research Applications segment was valued at US $0.76 billion in 2019 and is projected to grow at 16.99% CAGR over the forecast period to reach US $3.13 billion by 2027. Research Applications segment represented US $0.32 billion opportunity over 2019-2021 and estimated to create US $2.04 billion opportunity in 2027 over 2021.

Clinical Applications

Clinical Applications segment was valued at US $0.31 billion in 2019 and is projected to grow at 16.99% CAGR over the forecast period to reach US $1.27 billion by 2027. Clinical Applications segment represented US $0.13 billion opportunity over 2019-2021 and estimated to create US $0.83 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Research Organizations & Academic Institutes segment has the highest revenue of US $0.97 billion and is expected to grow at CAGR of 16.99% by 2027 Research Organizations & Academic Institutes segment has highest cagr growth of 16.99%.

Research Organizations & Academic Institutes

Research Organizations & Academic Institutes segment was valued at US $0.68 billion in 2019 and is projected to grow at 16.99% CAGR over the forecast period to reach US $2.80 billion by 2027. Research Organizations & Academic Institutes segment represented US $0.29 billion opportunity over 2019-2021 and estimated to create US $1.83 billion opportunity in 2027 over 2021.

Biopharmaceutical Companies

Biopharmaceutical Companies segment was valued at US $0.60 billion in 2019 and is projected to grow at 16.99% CAGR over the forecast period to reach US $2.46 billion by 2027. Biopharmaceutical Companies segment represented US $0.25 billion opportunity over 2019-2021 and estimated to create US $1.60 billion opportunity in 2027 over 2021.

Hospitals

Hospitals segment was valued at US $0.23 billion in 2019 and is projected to grow at 16.99% CAGR over the forecast period to reach US $0.94 billion by 2027. Hospitals segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.62 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $1.05 billion and is expected to grow at CAGR of 16.99% by 2027 North America segment has highest cagr growth of 16.99%.

North America

North America segment was valued at US $0.74 billion in 2019 and is projected to grow at 16.99% CAGR over the forecast period to reach US $3.02 billion by 2027. North America segment represented US $0.31 billion opportunity over 2019-2021 and estimated to create US $1.98 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $0.43 billion in 2019 and is projected to grow at 16.99% CAGR over the forecast period to reach US $1.77 billion by 2027. Europe segment represented US $0.18 billion opportunity over 2019-2021 and estimated to create US $1.16 billion opportunity in 2027 over 2021.

Asia Pacific

Asia Pacific segment was valued at US $0.27 billion in 2019 and is projected to grow at 16.99% CAGR over the forecast period to reach US $1.12 billion by 2027. Asia Pacific segment represented US $0.12 billion opportunity over 2019-2021 and estimated to create US $0.73 billion opportunity in 2027 over 2021.

Rest of the World

Rest of the World segment was valued at US $0.07 billion in 2019 and is projected to grow at 16.99% CAGR over the forecast period to reach US $0.28 billion by 2027. Rest of the World segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.19 billion opportunity in 2027 over 2021.